Experimental drug combo for advanced liver cancer tested, but trial stopped early
NCT ID NCT06320080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug combination (TQB2223 plus penpulimab) in 22 adults with advanced liver cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
-
Hubei Provincial Tumor Hospital
Wuhan, Hubei, 430079, China
-
Hunan Provincial Tumor Hospital
Changsha, Hunan, 410031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer
- Virus therapy takes on liver cancer in major trial